Phathom Pharmaceuticals, Inc. ( (PHAT) ) has released its Q2 earnings. Here is a breakdown of the information Phathom Pharmaceuticals, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, with a focus on their flagship product, VOQUEZNA®.
In their second quarter 2025 earnings report, Phathom Pharmaceuticals announced significant growth in VOQUEZNA prescriptions and a notable increase in net revenues, highlighting their strategic focus on profitability by 2026. The company also provided updates on their business strategy and regulatory achievements.
Key financial highlights from the report include a 49% increase in VOQUEZNA prescriptions since the last earnings report, resulting in net revenues of $39.5 million for the second quarter. The company has set a full-year revenue guidance of $165 million to $175 million for 2025. Additionally, Phathom has implemented strategic cost reductions and shifted its commercial strategy to prioritize high-value prescribers.
Phathom’s recent business developments include securing extended market exclusivity for VOQUEZNA through 2032 and strengthening its leadership team with the appointment of a new Chief Legal Officer. Despite a net loss of $75.8 million for the quarter, the company remains optimistic about its path to profitability, supported by robust commercial access and a targeted sales approach.
Looking ahead, Phathom Pharmaceuticals is poised to accelerate the adoption of VOQUEZNA and achieve profitability by 2026, as it continues to refine its commercial strategy and leverage its market exclusivity.